Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429778 | 0.85 | CYP2A6 (0.50) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL4030898 | 0.80 | IDO1 (0.46) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL15452989 | 0.80 | ALDH1A1 (0.47) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL332100 | 0.79 | GFER (0.42) | CYP2A6ALDH1A1KDM4E | |
| SCHEMBL10490665 | 0.78 | ALDH1A1 (0.46) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL14330452 | 0.78 | CYP2A6 (0.44) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL3976211 | 0.76 | CYP2A6 (0.52) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL13367648 | 0.76 | CYP2A6 (0.42) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL22322066 | 0.76 | CYP2A6 (0.42) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL77237 | 0.76 | CA2 (0.52) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344177-B2 | Albumin binding molecules and uses thereof | PHILOCHEM AG (CH) | 2013-01-01 | — | — | US | claimed |
| EP-2326350-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | Psma Development Company, L.L.C. (US) | 2011-06-01 | — | — | EP | claimed |
| US-20100172844-A1 | ALBUMIN BINDING MOLECULES AND USES THEREOF | PHILOCHEM AG (CH) | 2010-07-08 | — | — | US | claimed |
| WO-2010027513-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEVELOPMENT COMPANY, LLC (US) | 2010-03-11 | — | — | WO | claimed |
| EP-2094647-A2 | ALBUMIN BINDING MOLECULES AND USES THEREOF | Philochem AG (CH) | 2009-09-02 | — | — | EP | claimed |
| EP-1718667-A4 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH INC (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008053360-A2 | ALBUMIN BINDING MOLECULES AND USES THEREOF | PHILOCHEM AG (CH) | 2008-05-08 | — | — | WO | claimed |
| EP-1912677-A2 | PSMA ANTIBODY-DRUG CONJUGATES | Psma Development Company, L.L.C. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007002222-A2 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-01-04 | — | — | WO | claimed |
| EP-1718667-A2 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH, INC. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005082023-A2 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| EP-3057614-A1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | Psma Development Company, L.L.C. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015057250-A1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2015-04-23 | — | — | WO | disclosed |
| US-8344177-B2 | Albumin binding molecules and uses thereof | PHILOCHEM AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2326350-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | Psma Development Company, L.L.C. (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2094647-A2 | ALBUMIN BINDING MOLECULES AND USES THEREOF | Philochem AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008053360-A2 | ALBUMIN BINDING MOLECULES AND USES THEREOF | PHILOCHEM AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| EP-1912677-A2 | PSMA ANTIBODY-DRUG CONJUGATES | Psma Development Company, L.L.C. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007002222-A2 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-01-04 | — | — | WO | disclosed |
| US-4396553-A | Tetrahydronaphthalene and indane compounds useful as anti-tumor agents | HOFFMANN-LA ROCHE INC. (US) | 1983-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100172844-A1 | ALBUMIN BINDING MOLECULES AND USES THEREOF | ALB, FABP1, FABP2 | CYP2A6 2787/4885HSD17B10 3633/4885ALDH5A1 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.